Handelsbanken Fonder AB Has $23.04 Million Stock Position in GE HealthCare Technologies Inc. $GEHC

Handelsbanken Fonder AB increased its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 15.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 280,952 shares of the company’s stock after purchasing an additional 37,514 shares during the quarter. Handelsbanken Fonder AB’s holdings in GE HealthCare Technologies were worth $23,044,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Laurel Wealth Advisors LLC bought a new position in GE HealthCare Technologies in the fourth quarter worth $26,000. Optima Capital LLC bought a new position in GE HealthCare Technologies in the fourth quarter worth $27,000. Montag A & Associates Inc. lifted its position in GE HealthCare Technologies by 105.4% in the fourth quarter. Montag A & Associates Inc. now owns 341 shares of the company’s stock worth $28,000 after purchasing an additional 175 shares during the period. Maseco LLP bought a new position in GE HealthCare Technologies in the fourth quarter worth $29,000. Finally, Oakworth Capital Inc. lifted its position in GE HealthCare Technologies by 1,876.2% in the third quarter. Oakworth Capital Inc. now owns 415 shares of the company’s stock worth $31,000 after purchasing an additional 394 shares during the period. 82.06% of the stock is owned by institutional investors.

GE HealthCare Technologies Stock Up 4.4%

Shares of NASDAQ GEHC opened at $64.26 on Thursday. The stock has a market cap of $29.23 billion, a PE ratio of 15.37, a PEG ratio of 1.39 and a beta of 0.74. The business has a fifty day moving average of $68.79 and a two-hundred day moving average of $76.40. GE HealthCare Technologies Inc. has a 52-week low of $58.75 and a 52-week high of $89.77. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.95 and a current ratio of 1.22.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $0.99 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.08). The company had revenue of $5.13 billion for the quarter, compared to the consensus estimate of $5.04 billion. GE HealthCare Technologies had a net margin of 9.10% and a return on equity of 20.46%. The firm’s revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the business posted $1.01 earnings per share. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. As a group, equities research analysts expect that GE HealthCare Technologies Inc. will post 4.89 earnings per share for the current fiscal year.

Insider Activity at GE HealthCare Technologies

In other GE HealthCare Technologies news, insider Frank R. Jimenez purchased 1,750 shares of the business’s stock in a transaction that occurred on Thursday, April 30th. The stock was acquired at an average cost of $60.45 per share, with a total value of $105,787.50. Following the completion of the acquisition, the insider directly owned 93,932 shares of the company’s stock, valued at $5,678,189.40. This represents a 1.90% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Watkin Phoebe L. Yang purchased 1,000 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was acquired at an average cost of $63.01 per share, with a total value of $63,010.00. Following the completion of the acquisition, the director directly owned 13,702 shares of the company’s stock, valued at $863,363.02. The trade was a 7.87% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders purchased 11,847 shares of company stock valued at $719,555. Insiders own 0.36% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on GEHC. HSBC reduced their target price on GE HealthCare Technologies from $100.00 to $90.00 in a research report on Thursday, April 30th. Evercore set a $80.00 target price on GE HealthCare Technologies in a research report on Thursday, April 30th. Barclays reduced their target price on GE HealthCare Technologies from $87.00 to $78.00 and set an “equal weight” rating for the company in a research report on Thursday, April 30th. Mizuho reduced their target price on GE HealthCare Technologies from $90.00 to $80.00 in a research report on Thursday, April 30th. Finally, Morgan Stanley raised their target price on GE HealthCare Technologies from $80.00 to $85.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 4th. Nine investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, GE HealthCare Technologies has an average rating of “Moderate Buy” and an average price target of $80.21.

About GE HealthCare Technologies

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.